Jun Xue

585 total citations
13 papers, 460 citations indexed

About

Jun Xue is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jun Xue has authored 13 papers receiving a total of 460 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Cancer Research and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jun Xue's work include Circular RNAs in diseases (5 papers), Cancer-related molecular mechanisms research (5 papers) and MicroRNA in disease regulation (5 papers). Jun Xue is often cited by papers focused on Circular RNAs in diseases (5 papers), Cancer-related molecular mechanisms research (5 papers) and MicroRNA in disease regulation (5 papers). Jun Xue collaborates with scholars based in China, United States and Denmark. Jun Xue's co-authors include Te Liu, Yongyi Huang, Wei Cui, Hao Xi, Jiulin Chen, Huiying Chi, Chuan Chen, Jianli Hu, Gang Wu and Xiaofang Dai and has published in prestigious journals such as PLoS ONE, Cell Death and Differentiation and Gene.

In The Last Decade

Jun Xue

11 papers receiving 456 citations

Peers

Jun Xue
Jun Xue
Citations per year, relative to Jun Xue Jun Xue (= 1×) peers Guoqin Jiang

Countries citing papers authored by Jun Xue

Since Specialization
Citations

This map shows the geographic impact of Jun Xue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Xue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Xue more than expected).

Fields of papers citing papers by Jun Xue

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jun Xue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Xue. The network helps show where Jun Xue may publish in the future.

Co-authorship network of co-authors of Jun Xue

This figure shows the co-authorship network connecting the top 25 collaborators of Jun Xue. A scholar is included among the top collaborators of Jun Xue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jun Xue. Jun Xue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Zhang, Rui, Mo Wang, M. S. Frasinyuk, et al.. (2025). A novel amino-pyrimidine inhibitor suppresses tumor growth via microtubule destabilization and Bmi-1 down-regulation. Biochemical Pharmacology. 233. 116783–116783.
2.
Li, Jiahui, et al.. (2024). Understanding the role of ten-eleven translocation family proteins in kidney diseases. Biochemical Society Transactions. 52(5). 2203–2214.
3.
Liu, Huiqing, Weiji Weng, Rongjun Guo, et al.. (2020). Olig2 SUMOylation protects against genotoxic damage response by antagonizing p53 gene targeting. Cell Death and Differentiation. 27(11). 3146–3161. 25 indexed citations
4.
Zhong, Shan, Jun Xue, Jiaojiao Cao, et al.. (2020). The therapeutic value of XL388 in human glioma cells. Aging. 12(22). 22550–22563. 3 indexed citations
5.
Cui, Wei & Jun Xue. (2020). Circular RNA DOCK1 downregulates microRNA‐124 to induce the growth of human thyroid cancer cell lines. BioFactors. 46(4). 591–599. 34 indexed citations
6.
Xue, Jun, et al.. (2019). Lnc-THOR silencing inhibits human glioma cell survival by activating MAGEA6-AMPK signaling. Cell Death and Disease. 10(11). 866–866. 28 indexed citations
7.
Meng, Rui, Heng Tang, Huimin Wang, et al.. (2019). Design of a liver cancer‑specific selector for the analysis of circulating tumor DNA. Oncology Letters. 17(6). 5369–5376. 1 indexed citations
8.
Liu, Junfeng, Hongliang Shen, Chen Zhang, et al.. (2018). Fisetin decreases TET1 activity and CCNY/CDK16 promoter 5hmC levels to inhibit the proliferation and invasion of renal cancer stem cell. Journal of Cellular and Molecular Medicine. 23(2). 1095–1105. 46 indexed citations
9.
Liu, Te, Huiying Chi, Jiulin Chen, et al.. (2017). Curcumin suppresses proliferation and in vitro invasion of human prostate cancer stem cells by ceRNA effect of miR-145 and lncRNA-ROR. Gene. 631. 29–38. 123 indexed citations
10.
Yang, Fan, Yao Wang, Jun Xue, et al.. (2016). Effect of Corilagin on the miR-21/smad7/ERK signaling pathway in a schistosomiasis-induced hepatic fibrosis mouse model. Parasitology International. 65(4). 308–315. 44 indexed citations
11.
Shao, Xuejun, et al.. (2015). The Down-Regulation of MicroRNA-497 Contributes to Cell Growth and Cisplatin Resistance Through PI3K/Akt Pathway in Osteosarcoma. Cellular Physiology and Biochemistry. 36(5). 2051–2062. 49 indexed citations
12.
Xue, Jun, Jing Huang, Gang Peng, et al.. (2014). miR-141 suppresses the growth and metastasis of HCC cells by targeting E2F3. Tumor Biology. 35(12). 12103–12107. 28 indexed citations
13.
Shi, Liangliang, Sheng Zhang, Lilin Zhang, et al.. (2013). MiR-200c Increases the Radiosensitivity of Non-Small-Cell Lung Cancer Cell Line A549 by Targeting VEGF-VEGFR2 Pathway. PLoS ONE. 8(10). e78344–e78344. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026